📌 Key Takeaways
- Topic: Silica as an Adsorbent: How It Works and Common Applications
- Keywords: acidic silica sol
- Published: 2026-11-20 10:29:53
- Field: Silica (SiO₂) raw materials · Inorganic non-metallic materials · Chemicals
Silica for Rubber: Reinforcement Benefits, Grades and Compounding Tips
- Electronic Grade Silica: Purity Requirements, Specifications and Applications
- Silica for Tires: How It Reduces Rolling Resistance and Improves Wet Grip
- The common thermal therapy tactics include PTT and magnetothermal therapy (MTT). The integration of some certain functional factors into the MSNs can induce photothermal or magnetothermal influences by external light irradiation or by applying a magnetic field, respectively. During the thermal therapy, the locally generated thermal impact can cause irreversible damage to cells or tissues at the lesion, hence attaining targeted, non-invasive treatment. Regarding PTT, organic photothermal agents (PTAs) such as phthalocyanines and porphyrins can convert light energy into heat energy through non-radiative forms of decay-vibrational relaxation, 387, 388 as well as inorganic PTAs such as noble metals achieve photothermal conversion through LSPR effect, 389, 390 to produce the temperature needed for treatment. The single MSNs-based PTT modality has been thoroughly studied, and the current research focuses on the construction of integrated nanoplatform for diagnosis and treatment, or the development of multimodal synergistic treatment strategies. 391 A recent study reported by Kadria-Vili et al. demonstrated that MSNs could encapsulate Gd 2 O 3 NPs for dual T 1 /T 2 contrast and Au nanoshell PTA for NIR light-responsive PTT, thus giving clinicians the talent to " and treat". 392 In addition, MSNs were considered as a biocompatible and multifunctional nanoplatform for photothermal-immunotherapy against melanoma tumors, through merely integrating polydopamine PTA, ovalbumin model antigen, and ammonium bicarbonate antigen release promoter. 393 PTT suffers from insufficient penetration depth of NIR light, resulting in decreased treatment efficiency. In contrast, MTT can kill deep tumor cells by increasing the temperature to 43-48 °C, without causing significant side impacts to surrounding normal cells. 394 During the action, the magnetic NPs act as thermoseeds, exposed to an alternating magnetic field, absorbing magnetic energy and dissipating thermal energy through the magnetic relaxation influence. 395, 396 In a study reported by Yao et al., MSNs-based nanoplatform was proven to achieve synergistic therapeutic influence of PTT and MTT. They used MSNs shell to coat magnetic Fe 3 O 4, and served graphene quantum dots with photothermal conversion ability as the cap to control DOX release. After reaching the tumor acidic microenvironment and applying external light and magnetic field stimuli, DOX was released in a controlled manner and the accelerated tumor hyperthermia was attained. 397 In addition to PTT and MTT, the MSNs-mediated radiofrequency thermotherapy is also reported. Especially, the Si NPs themselves can serve as an excellent sensitizer to enhance the radiofrequency radiation effect. 398 A study by Tamarov et al. demonstrated that the radiofrequency radiation could more efficiently trigger temperature-responsive drug release than infrared light, therefore inhibiting tumor cell expansion even after one treatment. 399
- How to Choose a Silica Supplier: Key Criteria, Certifications and Red Flags
- Silica Supplier Mexico: Sourcing Options, Producers and Import Tips
- Zhang, R.-Q., Liu, Z.-Q., Luo, Y.-L., Xu, F. & Chen, Y.-S. Tri-stimuli responsive carbon nanotubes covered by mesoporous silica graft copolymer multifunctional materials for intracellular drug delivery. J. Ind. Eng. Chem. 80, 431-443 (2019). Post CAS Google Scholar
Silica HS Code: Correct Customs Classification for Silica, Quartz and Silica Gel
What is silica (SiO₂)?
best silica supplier Su, G. et al. Mesoporous silica doped with different water-soluble ligands to enhance the antibacterial performance of nano zinc oxides by coordination effect. Coll. Surf. A Physicochem. Eng. Asp. 640, 128414 (2022). Piece CAS Google Scholar
What is the difference between fumed silica and precipitated silica?
silica anti caking agent Guo, X. et al. The facile formation of hierarchical mesoporous silica nanocarriers for tumor-selective multimodal theranostics. Biomater. Sci. 9, 5237-5246 (2021). Article CAS PubMed Google Scholar
What drives silica raw material prices?
silica market size Clinical trials involving mesoporous silica have been ongoing since 2007, discussing its potential in diverse biomedical applications (Table 3 ). To date, the clinical trials have revealed the safety and good tolerability of silica in human subjects. In 2014, MSNs as oral delivery carriers for boosting the pharmacokinetic profile of drugs with limited aqueous solubility were reported. 500 A silica NPs-lipid hybrid formulation loading with ibuprofen (Lipoceramic-IBU) was prepared. The randomized, double-blind, single-dose oral administration study (20 mg ibuprofen) was conducted on 16 healthy male volunteers. The bioavailability of Lipoceramic-IBU was found to be 1.95 times higher than that of the commercial tablet Nurofen. 500 This result suggested the secure and effective use of silica-based NPs in mimicking food impacts to optimize the oral absorption of drugs with poor water solubility. In another clinical trial consisting of 12 participants in 2016, the bioavailability of ordered MSNs-based fenofibrate formulation raised by 54.1% after a single oral dose, when compared to the commercial formulation Lipanthyl. 39 Owing to the potentially perfect clinical outcomes of silica-based nanocarriers, the pharmacokinetics, safety, and metabolic profile of a hybrid core-shell silica NP (named Cornell dots, C dots) with a diameter of 6 nm functionalized with 124 I, targeting peptide cyclo-(Arg-Gly-Asp-Tyr), and Cy5 ( 124 I-cRGDY-PEG-C' dots) is first conducted in humans utilizing PET imaging and clinical tracer at clinical trials in 2014 (NCT01266096). 58 Results showed the good safety and reproducible PK signatures of C dots with the whole-body clearance half-time of 13-21 h after intravenous administration in patients, which is shorter than 111 In labeled liposomes and 131 I-labeled humanized monoclonal antibody A33. These findings verified the possibility of these NPs for cancer diagnostics in humans. 58 Similarly, 8 nm core-shell silica NPs encapsulated with Cy5.5 in the core and connected with cRGDY on the surface (cRGDY-PEG-Cy5.5-nanoparticles) were used in patients at nanomole doses for sentinel lymph nodes detection of head and neck melanoma at a phase 1/2 human clinical trial. 501 The incredible safety, accuracy, reliability, and high contrast of these particles for visual identification of sentinel lymph nodes are irreplaceable by other available imaging molecules presently, of which phase 2 clinical trial is ongoing and will be finished in 2024 (NCT02106598). Meanwhile, another two clinical trials based on C dots are carried out. In 2018, the 89 Zr-DFO-cRGDY-PEG-Cy5-C' dots tracers were first used in both surgical and non-surgical patients for PET-CT imaging of malignant brain tumors in phase 1 clinical trial (NCT03465618). The distribution and removal profiles from the body of these particles will also be assessed till 2023. In 2019, 64 Cu-NOTA-PSMA-PEG-Cy5.5-C' dots tracer was used in another human phase 1 clinical trial for guiding the surgery of prostate cancer by PET and MRI imaging (NCT04167969).As a nanocomposite with high safety and brilliant photothermal conversion efficiency, the silica-gold NPs have also been shown to be potential therapeutic agents for plasmonic photothermal therapy of atherosclerosis (NCT01270139), 502, 503 and photothermal ablation of tumors (NCT00848042, NCT04240639). 40 In addition, an engineered mesoporous silica (SiPore15) with particle size of 1.1-1.5 μm × 0.2-0.4 μm was developed by Baek et al., and they revealed that such pure synthetic amorphous silica could remarkably decrease long-term blood glucose levels, showing good promise for the treatment of prediabetes (NCT03823027). 504 In other clinical trials, an amorphous silica-containing bioactive scaffold, called Siloss, was used to promote bone regeneration, and could be replaced by natural bone due to its fully resorbable nature (NCT02639572), and the silica-calcium phosphate nanocomposite (SCPC) was developed as graft material for the reconstruction of the volume-deficient alveolar ridges (NCT05317039). In all, these clinical trials reveal the safety and efficacy of MSNs in diverse biomedical application scenarios.
/news/article.htmlDisclaimer: Prices and data are for reference only and do not constitute purchasing or investment advice. Please credit the source when republishing.